Eisai Co. Ltd, Radius Health deal

Radius now has worldwide rights to develop and commercialize RAD1901 after receiving Japanese rights from Eisai. In 2006, the pharma granted Radius ex-Japanese rights to develop and commercialize selective estrogen receptor modulators (SERMs). Radius will pay Eisai an upfront fee of $400,000. Eisai is eligible for undisclosed clinical and regulatory milestones under the expansion and for low single-digit royalties (see BioCentury, July 3, 2006). ...